Loading...
The idea of using plasma biomarkers for the diagnosis or prediction of Alzheimer disease (AD) is appealing given their relative ease of acquisition, but thus far studies investigating candidate proteins have yielded inconsistent results. In this study, researchers prospectively studied the relation between plasma amyloid-beta (Aβ) 42/40 levels and rate of cognitive decline as measured by serial Modified Mini-Mental State Examination (3MS) over a 9-year period. From a multiracial population of community-dwelling elders (mean baseline age, 74) in two metropolitan areas, 997 people with available serial 3MS scores and plasma (not cerebrospinal fluid) Aβ measurements reported their education level and underwent a validated neuropsychological as…